Modern Healthcare's CEO Power Panel survey indicates healthcare leaders still fear unbridled drug costs and wonder if the industry has reached a breaking point.
Hospitals have long been bedeviled by shortages and price spikes for the generic drugs that are essential to their day-to-day operations.
The new health system-led generic-drug company sent a shockwave through the healthcare industry, but experts warned that it would take plenty of time and capital to ultimately lower drug prices and mitigate shortages.
A new study found the CMS' Medicare Part D program could have saved $3.4 billion between 2012 and 2015 if the agency required generic substitutes for 62 brand-name drugs that weren't covered by the two largest pharmacy benefit managers.
In his initial confirmation testimony, former pharma executive and HHS secretary nominee Alex Azar said he would stop drug manufacturers from gaming the system and blocking generic competitors from the market.
The FDA's new guidance aims to make it easier for generic firms to plan how they can copy complex drugs like epinephrine auto-injectors, which should ultimately lower pharmaceutical prices.
Connecticut and 45 other states are seeking to expand a federal antitrust lawsuit against generic-drug makers to include more manufacturers and medications, as well as senior executives at two companies.
Chip Davis, the president and CEO of the Association for Accessible Medicines, talks about the need for more competition to bring down healthcare costs.
Making actual generic drug acquisition costs available to third-party payers would empower health plans to negotiate lower rates and essentially level the playing field in a pharmaceutical supply chain that's shrouded in secrecy, according to a new paper.
Sanofi's commitment to limit prices to the rise in the National Health Expenditure Data Accounts—estimated to be 5.6% annually from 2016 to 2025—is not enough, healthcare experts said.
The rising prices of branded drugs are affecting consumers, providers and payers alike, which have seen drug prices jump 18% every year since 2010.
Angered by skyrocketing drug prices, a pair of senators on Wednesday urged Congress to block companies from cornering the market on old, off-patent drugs.